Articles tagged with Sickle Cell Anemia
A study suggests that hydroxyurea alters the developmental process of ovarian follicles but not their quantity. Ovarian tissue samples from patients with SCD showed no significant difference in primordial follicle density between those who received hydroxyurea and those who did not.
A study by Texas A&M University researchers found that individuals with sickle cell disease who experience a delay of more than six months after transferring from pediatric to adult care are twice as likely to be hospitalized compared to those who transition in less than two months. The research suggests that early introductions to adu...
Researchers found that patients with sickle cell disease experience significant distress from anticipating and attending emergency departments to manage acute pain flares. The study also revealed stigma and racism in care settings, leading to a lack of control over pain management plans.
The Indiana Sickle Cell Dashboard presents interactive visualizations of the disease's prevalence and burden across an entire state, offering a comprehensive picture of those living with sickle cell. The dashboard provides rates per 100,000 population, allowing for comparisons between states or areas around the world.
Individuals living with sickle cell disease who experience delays in transitioning to adult care are twice as likely to be hospitalized, according to a study. Patients who transition within six months have more outpatient visits and better health outcomes.
A phase 3 clinical trial found that 96.7% of patients did not experience severe vaso-occlusive crises, and all remained hospitalization-free for at least one year after receiving the gene therapy CASGEVY.
Researchers discovered a novel brain network condition called 'explosive synchronization' that correlates with pain crises in sickle cell disease. This finding could lead to predicting and preventing severe episodes of pain, improving patient outcomes.
Researchers found that riociguat significantly improved blood pressure and reduced the risk of serious adverse events compared to a placebo treatment. The study showed promising results for this potential new treatment to manage complications from sickle cell disease, paving the way for larger clinical trials.
A recent article recommends measuring meaningful outcomes such as pain interference, self-efficacy, and physical functioning to improve the evidence-base for music therapy within sickle cell disease populations. Music therapists can play an important role in chronic pain management by addressing stress, depressed mood, and loneliness.
A study by Children's Hospital Los Angeles found that only about 20% of young children with sickle cell anemia received adequate preventative antibiotics, while about half received annual brain ultrasounds to assess stroke risk. These findings highlight the need for improved care and support for children with this chronic disease.
A new meta-analysis published in eClinicalMedicine found that individuals with sickle cell disease or the sickle cell trait are more likely to die from COVID-19 compared to the general population. The study analyzed data from over 1,900 patients with sickle cell disease and 8,700 carriers of the sickle cell trait.
Researchers at University Hospitals Cleveland Medical Center developed a quality improvement project using routine pain screening, revealing 32.7% of patients reported persistent or chronic pain, with music therapy and art therapy preferred for managing pain.
A recent study published in the journal Blood revealed that hydroxyurea treatment resulted in a 60% reduction in severe or invasive infections among Ugandan children with sickle cell anemia. The findings provide powerful justification for hydroxyurea's use as a standard of care in Africa, which could ultimately save countless lives.
A cross-sectional study of over 6,500 adults aged 65+ found that older adults spent an average of 20.7 days per year receiving healthcare outside the home. The 'health care contact days' metric can help evaluate care and identify areas for improvement, such as coordinating tests with visits and reducing Friday office visits.
A new study reveals that people with sickle cell disease are nearly two times less likely to get vaccinated against COVID-19 compared to those without the disease. Vaccination rates were particularly low in children and teens with sickle cell disease, who face a higher risk of hospitalization and death if infected.
A recent study reveals that two-thirds of babies born with sickle cell disease are born in areas scoring high or very high on the scale of social vulnerability. This highlights the need for targeted efforts to support families affected by this genetic blood disease.
Researchers at University of Cincinnati Cancer Center present Phase 2 clinical trial results for a new BTK inhibitor treatment that offers potential for improved efficacy and safety in chronic lymphocytic leukemia. The study also explores the use of IRAK4 inhibitors to target acute myeloid leukemia cells, with promising results.
Researchers discovered a link between gene therapy and the accumulation of stem cells with genetic mutations, which can lead to accelerated growth and increased blood cancer risk. The study suggests that younger patients may be safer candidates for gene therapy due to fewer genetic mutations.
Individuals with severe sickle cell disease express willingness to accept gene therapy risks for a potential cure. Gene therapies offer higher chances of eliminating symptoms and extending life expectancy, but also come with significant risks.
A recent study has shown that pneumococcal conjugate vaccines have significantly reduced the rate of invasive pneumococcal infection among children with sickle cell disease. The overall rate of IPD decreased by 87% in children under 4 years old, and by 80% in those aged 5 to 9.
A new clinical trial published in the New England Journal of Medicine indicates that stem cell gene therapy may offer a promising, curative treatment for sickle cell disease. The therapy was shown to decrease vaso-occlusive events and increase production of fetal hemoglobin, providing relief from the painful condition.
New research led by Nansi Boghossian found that sickle cell disease contributes to racial disparities in severe maternal morbidity, with Black individuals at least 1.5 times more likely to experience complications. The study suggests preconception care and management are critical for improving pregnancy outcomes for patients with sickl...
Researchers have made a significant discovery in gene therapy, showing that genetically engineered blood stem cells can be created while still in the bone marrow. This approach eliminates the need for chemotherapy and transplantation of corrected cells, cutting costs and improving access to critical treatments.
The program found 1,695 persons in Indiana with sickle cell disease, with a median age of 21 and 87% Black. The data will inform clinical care, identify gaps in access to care, and guide lawmakers.
Gang Bao's lab receives a 4-year, $2.6 million grant from the National Institutes of Health to investigate the safety and efficacy of using gene editing treatments like CRISPR-Cas9 to treat sickle cell disease. The team aims to understand the mechanisms behind large gene modifications and their biological consequences.
A recent study suggests that the global mortality burden of Sickle Cell Disease (SCD) is approximately 11 times higher than previously recorded, with an estimated 376,000 deaths in 2021. The Commission highlights the need for increased funding and access to treatments such as hydroxyurea, blood transfusions, and malaria prevention meth...
Researchers use base editing technology to restart fetal hemoglobin expression in SCD patient cells, achieving higher and more stable levels than other genome editing technologies. The approach has potential as a 'one-size-fits-all' treatment for all mutations that cause SCD and beta-thalassemia.
Researchers have discovered that gene editing technologies may introduce unintended mutations and damage to DNA in early human embryos. The study found that most cells repair breaks in the DNA using non-homologous end joining, which can lead to additional genetic abnormalities.
A new study reveals sickle cell disease is far deadlier than its textbook description, with a total mortality burden of 373,000 deaths in 2021. The condition disproportionately affects children, adolescents, and young adults worldwide, highlighting the need for universal newborn screening and early intervention.
This systematic analysis reports a significant global increase in sickle cell disease prevalence and mortality. The study reveals that sickle cell disease affects millions worldwide, with the highest burden in low- and middle-income countries.
An observational study of 329,000 Medicare admissions found that older persons receiving hospital care from allopathic (M.D.) or osteopathic (D.O.) physicians experience similar quality and cost of care. Researchers also highlight systemic health inequities faced by persons with sickle cell disease.
A cross-sectional analysis of 2,200 individuals with sickle cell disease found associations between employment status, sex, age, and depression with pain frequency. Comprehensive treatment for SCD must consider the full experiences of patients, including mental health impacts on pain reduction.
A team of researchers is exploring the potential of HDAC inhibitors to treat sickle cell disease by reactivating the fetal hemoglobin gene. Early evidence suggests that panobinostat, a specific inhibitor, can increase fetal hemoglobin levels in red blood cells and mouse models.
A new approach, STING-seq, combines genetic association studies, gene editing, and single-cell sequencing to identify causal variants and genetic mechanisms for blood cell traits. This method can help scientists identify drug targets for diseases with a genetic basis.
Researchers used prime editing to correct the mutation that causes sickle cell disease, restoring normal blood parameters in mice. The approach showed promising results with up to 41% conversion of mutated cells to healthy ones.
A new study published in Blood Advances found that the average life expectancy of publicly insured individuals with sickle cell disease is roughly 52.6 years, which is significantly lower than the overall US life expectancy of 73.5 years for men and 79.3 years for women. The study also revealed worse survival outcomes among those insur...
A new study found that less than 4% of people with sickle cell disease have prescriptions for newer FDA-approved pain-relieving drugs, despite their availability. The study also revealed significant gaps in prescription patterns by geographic region and age group, emphasizing the need for education and access to treatment options.
Researchers at University Hospitals Cleveland Medical Center discovered that S-nitrosohemoglobin senses areas with insufficient oxygen and restores blood flow for oxygenation. This breakthrough opens up a new line of drug development to correct poor tissue oxygenation, including peripheral artery disease and sickle cell disease.
A new study found that massage therapy significantly reduces pain, stress, and anxiety in children, adolescents, and young adults with cancer or sickle cell disease. The study published in Pediatric Blood & Cancer reports clinically significant benefits from massage therapy, highlighting its potential as a non-pharmacologic treatment o...
Researchers discovered that bone marrow transplants can halt the development and progression of brain blood vessel disease in adults with sickle cell disease. The study found that receiving stem cell transplants led to positive changes in blood vessels, reducing the risk of stroke among patients with the condition.
Researchers developed a microfluidic device to model the spleen's filtration function in patients with sickle cell disease. The study found that low oxygen levels can cause the spleen's filters to become clogged, while boosting oxygen levels can unclog them, potentially explaining how blood transfusions help patients.
A new study found that music therapy resulted in clinically significant reductions in pain and anxiety for patients with cancer and sickle cell disease. Patients with SCD who received music therapy also reported significantly higher pain and anxiety at baseline compared to those without SCD.
Researchers at Rice University have developed a procedure to quantify unintended changes that accompany on-target CRISPR-Cas9 gene editing, potentially threatening the efficacy and safety of therapies. The new method uses single-molecule sequencing with unique molecular identifiers to detect large deletions, insertions, and chromosomal...
Researchers found a direct connection between low oxygen conditions and increased fetal hemoglobin production in adults. A drug that activates the cellular response to low oxygen could potentially treat sickle cell disease by promoting HbF production, which has therapeutic benefits.
Researchers developed new educational materials to help individuals with sickle cell disease and their support networks learn about gene therapy clinical trials, benefits, risks, and treatment options. The project aims to facilitate engagement between the community and those conducting relevant clinical trials.
A new gene therapy for sickle cell disease was tested in mice but proved ineffective due to the complex genetic make-up of the Berkeley mice. The study suggests that researchers should carefully consider the genetics of the mice used to test human diseases.
The Brigham and Women's Hospital will implement and evaluate an integrated service delivery model (PEN-Plus) for severe chronic noncommunicable diseases, such as type 1 diabetes and rheumatic heart disease, in eight low- and lower-middle-income countries. The initiative aims to enable one million of the world's poorest children and you...
A study by RCSI University of Medicine and Health Sciences has identified barriers and motivators to blood donation for people from ethnic minority groups in Ireland. Factors that motivate people from minority ethnic backgrounds to give blood include religious reasons and a desire to help others in their own communities.
Researchers found that people living with SCD have more medical appointments and urgent care visits, leading to higher out-of-pocket costs of $1,300 annually. The study suggests that curative therapies could reduce these costs, but accessing them will depend on conversations among policymakers, insurers, and patients.
A new study reveals that individuals with sickle cell disease spend approximately $1.7 million on lifetime medical expenses, highlighting the significant economic burden of living with this disease. The study found that out-of-pocket costs for those with private insurance plans can be as high as 5-10% of their annual income.
A new study found that many adolescent and young adult men with sickle cell disease are unaware of potential fertility issues associated with the disorder. The research suggests a need for accessible fertility education and testing options to address this knowledge gap, particularly in how SCD and treatments may affect fertility.
A UCLA-led team has created a roadmap tracing each step in human blood stem cell development, providing a blueprint for producing fully functional blood stem cells. The map could help expand treatment options for blood cancers and inherited disorders.
A systematic review and meta-analysis found that SGLT2 inhibitors reduce hospitalizations and cardiovascular deaths in heart failure patients, regardless of diabetes status. The analysis also warned of increased genital infections associated with treatment.
Researchers used CRISPR gene editing to understand how deletions in one area of the genome affect nearby genes. They found that deleting a small region led to increased foetal globin expression and reduced adult globin levels, suggesting a key mechanism for asymptomatic patients with sickle cell disease.
The Patient-Centered Outcomes Research Institute (PCORI) Board of Governors approved funding for 12 new comparative clinical effectiveness research studies focusing on maternal health, autism, and urinary incontinence. These studies will improve healthcare delivery and health outcomes in real-world settings.
A recent study suggests that gene therapy could be a possible cure for sickle cell disease, with the added benefit of preventing complications and extending lifespan. However, the high cost and limited accessibility of this treatment pose significant challenges for patients worldwide.
A new study found that music therapy sessions improved patients' ability to manage chronic pain and enhance their quality of life. The intervention, which included music-based breathing exercises and progressive muscle relaxation, was feasible, acceptable, and beneficial among adults with Sickle Cell Disease.
A recent study found that gene therapy delivery vectors were unlikely to cause the blood malignancies reported in trials; however, the exact cause remains a mystery. The study's results suggest that cancer risk in sickle cell disease may be more complex than initially thought, warranting further investigation.
A new gene therapy called LentiGlobin has been shown to completely eliminate episodes of severe pain caused by sickle cell disease and restore blood cells to their normal shape. The treatment uses a patient's own stem cells and has the potential to give people with this disease their life back.
A doctoral student at Texas A&M University has discovered blood outgrowth endothelial cells (BOECs) as an alternative to induced pluripotent stem cells (IPSCs) for organs-on-chips, offering a cheaper and more accessible option for patient-specific research. The new cells can be isolated from just 50-100 milliliters of blood and have sh...